ClinicalTrials.gg
CompletedNCT03815058IMCODE001Updated Jan 30, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

A Phase 2 interventional study of Autogene cevumeran and Pembrolizumab in Advanced Melanoma, sponsored by Genentech, Inc.. Completed at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Melanoma by Hoffmann-La Roche — none open to participants now, 4 under way, none of them phase 3. Melanoma · Hoffmann-La Roche.

Enrollment
17th of 52
131 · median 53
Started
2018
with 3 others
Phase 2
15 of 57
none open now
Registered
48th of 57
by date

Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 17th largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 2, and was the 48th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 57 studies in Melanoma by Hoffmann-La Roche is open now. The open studies under Melanoma, anywhere →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies in Melanoma by Hoffmann-La Roche as a file.
02

Study summary

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

03

Conditions studied

  • Advanced Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed (recurrent or de novo Stage IV) or unresectable locally advanced (Stage IIIC or IIID) cutaneous, acral, or mucosal melanoma;
  • (ECOG) Performance Status of 0 or 1;
  • >/= 12 weeks;
  • Adequate hematologic and end-organ function;
  • Naive to prior systemic anti-cancer therapy for advanced melanoma with some exceptions;
  • Tumor specimen availability;
  • per v1.1.

Exclusion criteria

Exclusion criteria:

  • Ocular/uveal melanoma;
  • Any anti-cancer therapy with the exceptions as specified in the protocol;
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) ;
  • Previous splenectomy;
  • History of disease;
  • Prior bone marrow transplantation or prior solid organ transplantation;
  • Positive test for (HIV) infection;
  • Active or C or tuberculosis;
  • Significant cardiovascular disease;
  • Known liver disease.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Safety Run-in Period: Autogene Cevumeran + Pembrolizumab

    Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of autogene cevumeran.

    Biological: Autogene cevumeran · Drug: Pembrolizumab

  • Active comparator
    Randomized Period: Arm A: Pembrolizumab

    Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with autogene cevumeran plus pembrolizumab (Arm B) after confirmed disease progression.

    Drug: Pembrolizumab

  • Experimental
    Randomized Period: Arm B: Autogene Cevumeran + Pembrolizumab

    Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of autogene cevumeran.

    Biological: Autogene cevumeran · Drug: Pembrolizumab

Interventions

  • Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.

    Also known as: RO7198457

  • Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.

    Also known as: Keytruda

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization

    PFS was defined as the time from randomization to the first documented PD as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (KM) method was used to estimate median PFS.

    Time frame: From randomization to PD or death (up to approximately 60 months)

Secondary outcomes

  1. Objective Response Rate (ORR) According to RECIST V.1.1 After Randomization

    ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off to the nearest whole number.

    Time frame: Up to approximately 60 months

  2. Overall Survival (OS) After Randomization

    OS was defined as the time from randomization to death from any cause. KM method was used to estimate the median OS.

    Time frame: From randomization to death (up to approximately 63 months)

  3. Duration of Response (DOR) According to RECIST V.1.1 After Randomization

    DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. DOR was estimated using the KM methodology.

    Time frame: Up to approximately 60 months

  4. Change From Baseline in Global Health Status (GHS)/Health-related Quality of Life (HRQoL) Score Assessed by European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 consists of 30 questions that assess participant functioning (physical, emotional, role, cognitive, and social), symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Change in HRQoL was assessed using participant responses to questions regarding GHS (Question 29: GHS; "How would you rate your overall health during the past week?") and QoL (Question 30: QoL; "How would you rate your overall quality of life during the past week?") and were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized. Scores range from 0-100. A higher score indicates a better QoL.

    Time frame: Baseline, Day 1 of Cycles 1 to 34, time of first PD, time to last dose, treatment discontinuation and study drug completion (up to approximately 29 months) (1 cycle = 21 days)

  5. ORR According to RECIST V.1.1 After Crossover

    ORR was defined as the percentage of participants with a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.

    Time frame: Up to 54.7 months

  6. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: Baseline up to 90 days after the final dose of study drug (Safety run-in and randomized stage: up to 32 months; Cross-over stage: up to 24 months)

07

Results

Posted Jan 30, 2026

Participant flow

A total of 131 participants with previously untreated advanced melanoma took part in the study at 40 investigative sites across the United States, Germany, Australia, Spain, Belgium, and the United Kingdom from 21 December 2018 to 21 January 2025. The study consists of an initial safety run-in stage followed by a randomized stage (Arm A \& Arm B). Participants in Arm A had an option to crossover to Arm B after confirmed disease progression (PD), if crossover eligibility criteria were met.

Safety Run-in Stage
Participant flow — Safety Run-in Stage
MilestoneSafety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Crossover: Pembrolizumab + RO7198457
Started6000
Safety-evaluable (se) population6000
Completed0000
Not completed6000
Withdrew: Death2000
Withdrew: Study ended by sponsor4000
Randomized Stage
Participant flow — Randomized Stage
MilestoneSafety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Crossover: Pembrolizumab + RO7198457
Started041840
Se population044800
Completed0000
Not completed041840
Withdrew: Death013290
Withdrew: Lost to follow-up0240
Withdrew: Study ended by sponsor014420
Withdrew: Withdrawal by subject0290
Withdrew: Discontinued due to pd to receive cross-over treatment01000
Cross-over Treatment
Participant flow — Cross-over Treatment
MilestoneSafety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Crossover: Pembrolizumab + RO7198457
Started00010
Se population00010
Completed0000
Not completed00010
Withdrew: Death0002
Withdrew: Study ended by sponsor0007
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryProgression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization

PFS was defined as the time from randomization to the first documented PD as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (KM) method was used to estimate median PFS.

Time frame:
From randomization to PD or death (up to approximately 60 months)
Reported as:
Median · months
Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization
monthsArm A: PembrolizumabArm B: Pembrolizumab + RO7198457
Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization7.9 (2.8 to 22.7)8.3 (6.9 to 26.9)
Statistical analysis
  • Arm A: Pembrolizumab vs Arm B: Pembrolizumab + RO7198457 · Log Rank · p = 0.3284 · Hazard ratio (hr): 0.79 · 95% CI 0.49 to 1.27
SecondaryObjective Response Rate (ORR) According to RECIST V.1.1 After Randomization

ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off to the nearest whole number.

Time frame:
Up to approximately 60 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) According to RECIST V.1.1 After Randomization
percentage of participantsArm A: PembrolizumabArm B: Pembrolizumab + RO7198457
Objective Response Rate (ORR) According to RECIST V.1.1 After Randomization48.8 (32.26 to 65.30)41.7 (30.53 to 52.80)
SecondaryOverall Survival (OS) After Randomization

OS was defined as the time from randomization to death from any cause. KM method was used to estimate the median OS.

Time frame:
From randomization to death (up to approximately 63 months)
Reported as:
Median · months
Overall Survival (OS) After Randomization
monthsArm A: PembrolizumabArm B: Pembrolizumab + RO7198457
Overall Survival (OS) After RandomizationNA (19.6 to NA)62.2 (41.8 to NA)
SecondaryDuration of Response (DOR) According to RECIST V.1.1 After Randomization

DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator according to RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. DOR was estimated using the KM methodology.

Time frame:
Up to approximately 60 months
Reported as:
Median · months
Duration of Response (DOR) According to RECIST V.1.1 After Randomization
monthsArm A: PembrolizumabArm B: Pembrolizumab + RO7198457
Duration of Response (DOR) According to RECIST V.1.1 After RandomizationNA (19.8 to NA)NA (36.1 to NA)
SecondaryChange From Baseline in Global Health Status (GHS)/Health-related Quality of Life (HRQoL) Score Assessed by European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 consists of 30 questions that assess participant functioning (physical, emotional, role, cognitive, and social), symptom scales (fatigue, nausea and vomiting, pain), GHS/QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Change in HRQoL was assessed using participant responses to questions regarding GHS (Question 29: GHS; "How would you rate your overall health during the past week?") and QoL (Question 30: QoL; "How would you rate your overall quality of life during the past week?") and were scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores were standardized. Scores range from 0-100. A higher score indicates a better QoL.

Time frame:
Baseline, Day 1 of Cycles 1 to 34, time of first PD, time to last dose, treatment discontinuation and study drug completion (up to approximately 29 months) (1 cycle = 21 days)
Reported as:
Mean · score on a scale
Change From Baseline in Global Health Status (GHS)/Health-related Quality of Life (HRQoL) Score Assessed by European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire (EORTC QLQ-C30)
score on a scaleArm A: PembrolizumabArm B: Pembrolizumab + RO7198457
Baseline64.74 ± 24.6773.39 ± 21.56
Change at Cycle 1 Day 1—0.00 ± 0.00
Change at Cycle 2 Day 1-1.85 ± 17.72-1.37 ± 14.40
Change at Cycle 3 Day 12.60 ± 16.730.54 ± 16.69
Change at Cycle 4 Day 13.74 ± 16.45-3.70 ± 19.48
Change at Cycle 5 Day 13.53 ± 19.32-1.84 ± 15.56
Change at Cycle 6 Day 10.00 ± 20.57-6.03 ± 22.51
Change at Cycle 7 Day 12.27 ± 15.04-1.01 ± 15.85
Change at Cycle 8 Day 10.83 ± 10.080.15 ± 18.35
Change at Cycle 9 Day 1-2.92 ± 12.76-1.19 ± 15.77
Change at Cycle 10 Day 14.39 ± 14.26-3.72 ± 15.43
Change at Cycle 11 Day 10.52 ± 16.521.06 ± 14.29
Change at Cycle 12 Day 11.56 ± 13.34-4.07 ± 14.82
Change at Cycle 13 Day 11.11 ± 24.570.00 ± 13.61
Change at Cycle 14 Day 12.98 ± 12.49-2.03 ± 13.54
Change at Cycle 15 Day 10.56 ± 13.16-3.07 ± 16.37
Change at Cycle 16 Day 10.64 ± 16.12-1.72 ± 15.04
Change at Cycle 17 Day 14.86 ± 15.27-2.60 ± 15.62
Change at Cycle 18 Day 15.00 ± 18.51-4.57 ± 17.72
Change at Cycle 19 Day 10.00 ± 19.64-1.61 ± 14.18
Change at Cycle 20 Day 15.56 ± 11.79-1.67 ± 14.42
Change at Cycle 21 Day 19.26 ± 12.80-0.31 ± 15.41
Change at Cycle 22 Day 111.46 ± 12.55-1.79 ± 17.18
Change at Cycle 23 Day 18.33 ± 9.32-2.68 ± 17.43
Change at Cycle 24 Day 12.78 ± 13.82-3.87 ± 22.28
Change at Cycle 25 Day 11.85 ± 18.53-4.81 ± 18.59
Change at Cycle 26 Day 15.21 ± 14.04-3.40 ± 14.85
Change at Cycle 27 Day 10.00 ± 8.91-2.47 ± 15.64
Change at Cycle 28 Day 1-4.76 ± 20.89-2.67 ± 17.47
Change at Cycle 29 Day 12.08 ± 14.60-2.47 ± 15.98
Change at Cycle 30 Day 1-1.04 ± 5.34-7.69 ± 17.47
Change at Cycle 31 Day 13.13 ± 14.73-3.67 ± 18.65
Change at Cycle 32 Day 17.29 ± 14.39-3.21 ± 18.72
Change at Cycle 33 Day 15.21 ± 13.32-4.81 ± 18.59
Change at Cycle 34 Day 17.29 ± 13.68-5.00 ± 18.16
Change at Time of First PD-1.47 ± 26.06-4.17 ± 19.43
Change at Time of Last Dose-5.65 ± 25.40-7.30 ± 23.55
Change at Treatment Discontinuation-2.27 ± 26.75-11.07 ± 18.43
SecondaryORR According to RECIST V.1.1 After Crossover

ORR was defined as the percentage of participants with a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.

Time frame:
Up to 54.7 months
Reported as:
Number · percentage of participants
ORR According to RECIST V.1.1 After Crossover
percentage of participantsCrossover: Pembrolizumab + RO7198457
ORR According to RECIST V.1.1 After Crossover40.0 (4.64 to 75.36)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

Time frame:
Baseline up to 90 days after the final dose of study drug (Safety run-in and randomized stage: up to 32 months; Cross-over stage: up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsSafety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Crossover: Pembrolizumab + RO7198457
Number of Participants With Adverse Events (AEs)6437910

Adverse events

Collected over Baseline up to 90 days after the final dose of study drug (Safety run-in and randomized stage: up to 32 months; Cross-over stage: up to 24 months); All-cause Mortality: up to approximately 63 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Run-in2/6 (33.3%)3/6 (50%)6/6 (100%)
Arm A: Pembrolizumab14/44 (31.8%)16/44 (36.4%)40/44 (90.9%)
Arm B: Pembrolizumab + RO719845730/80 (37.5%)25/80 (31.3%)78/80 (97.5%)
Crossover: Pembrolizumab + RO71984573/10 (30%)4/10 (40%)9/10 (90%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventSafety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Crossover: Pembrolizumab + RO7198457
ChillsGeneral disorders1/60/440/800/10
CholecystitisHepatobiliary disorders1/60/440/800/10
Cytokine release syndromeImmune system disorders1/60/442/801/10
Device related infectionInfections and infestations1/60/440/800/10
Enteritis infectiousInfections and infestations1/60/440/800/10
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/65/443/800/10
DuodenitisGastrointestinal disorders0/60/440/801/10
DeathGeneral disorders0/60/440/801/10
Liver function test abnormalInvestigations0/60/440/801/10
Small intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/440/801/10
Most frequent other events
Showing 10 of 142
Most frequent other events
EventSafety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Crossover: Pembrolizumab + RO7198457
FatigueGeneral disorders5/613/4436/805/10
Infusion related reactionInjury, poisoning and procedural complications0/62/4462/805/10
NauseaGastrointestinal disorders3/611/4422/802/10
Influenza like illnessGeneral disorders3/64/4414/801/10
Cytokine release syndromeImmune system disorders3/60/442/801/10
ArthralgiaMusculoskeletal and connective tissue disorders3/67/4420/802/10
HypertensionVascular disorders2/65/449/804/10
HypothyroidismEndocrine disorders2/62/449/801/10
ChillsGeneral disorders2/61/443/801/10
Oedema peripheralGeneral disorders2/61/447/800/10

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Safety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Total
Mean63.3 ± 11.062.4 ± 14.463.6 ± 14.263.2 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Safety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Total
Female1112739
Male5305792
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Safety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Total
Hispanic or Latino0112
Not Hispanic or Latino63969114
Unknown or Not Reported011415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Run-inArm A: PembrolizumabArm B: Pembrolizumab + RO7198457Total
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White63880124
More than one race0000
Unknown or Not Reported0325
08

Study locations

41 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • University of California San Diego Moores Cancer Center
    La Jolla, California 92037, United States
  • UCSF Comprehensive Cancer Ctr
    San Francisco, California 94115, United States
  • University of Colorado
    Denver, Colorado 80262, United States
  • Cancer Specialists
    Jacksonville, Florida 32256, United States
  • Moffitt McKinley Outpatient Center
    Tampa, Florida 33612, United States
  • Atlanta Cancer Care
    Alpharetta, Georgia 30005, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital.
    Boston, Massachusetts 02114, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Case Western Research University
    Cleveland, Ohio 44106-5067, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Sarah Cannon Research Institute / Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Intermountain Surgical Oncology
    Murray, Utah 84107, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • University of Virginia
    Charlottesville, Virginia 22906, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Alfred Hospital
    Melbourne, Victoria 3181, Australia
  • St. John of God - Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
  • Antwerp University Hospital
    Edegem, 2650, Belgium
  • ZAS Sint Augustinus Wilrijk
    Wilrijk, 2610, Belgium
  • Elbe Kliniken Stade-Buxtehude GmbH
    Buxtehude, 21614, Germany
  • Universitätsklinikum Koeln
    Cologne, 50937, Germany
  • Universitatsklinikum Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Uni Schleswig-Holstein
    Lübeck, 23562, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Hautklinik und Poliklinik
    Mainz, 55131, Germany
  • Med. Fakultat Mannheim der Universitat Heidelberg
    Mannheim, 68167, Germany
  • Fachklinik Hornheide
    Münster, 48157, Germany
  • Universitätshautk. Tübingen
    Tübingen, 72076, Germany
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Instituto Oncológico Dr. Rosell
    Barcelona, 08028, Spain
  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario La Paz
    Madrid, 280146, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Barts and The London
    London, EC1M 6BQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2025, 73 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 73 months is above that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2019
First posted
Jan 24, 2019
StartActual
Dec 21, 2018
Primary completionActual
Jan 21, 2025
CompletionActual
Jan 21, 2025
Results first posted
Jan 30, 2026
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03815058
Lead sponsor
Genentech, Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Jan 24, 2019
Start date
Dec 21, 2018
Primary completion
Jan 21, 2025
Completion
Jan 21, 2025
Results posted
Jan 30, 2026
Last update
Jan 30, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autogene cevumeran

Start the discussion